Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solrikitug - Uniquity Bio

Next Previous
Drug Profile

Solrikitug - Uniquity Bio

Alternative Names: MK-8226; NSI-8226

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Uniquity Bio
  • Class Anti-inflammatories; Antiallergics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Thymic stromal lymphopoietin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Eosinophilic oesophagitis
  • Discontinued Atopic dermatitis

Most Recent Events

  • 14 Jul 2025 Uniquity Bio plans a phase III trial in Eosinophilic oesophagitis, Asthma and Chronic obstructive pulmonary disease (SC)
  • 20 Jun 2025 Uniquity One initiates a phase I pharmacokinetics trial in healrhy volunteers in Australia (SC) (NCT06868082)
  • 28 Feb 2025 Pharmacodynamic data from a preclinical trial in Asthma presented at the 2025 Annual Meeting of the American Academy of Allergy, Asthma and Immunology/World Allergy Organization Joint Congress (AAAAI-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top